Comprehensive studies on the renal kallikrein-kinin system in essential hypertension. 1986

Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura

In order to investigate the role of the renal kallikrein-kinin (K-K) system in normal (NRH) and low renin (LRH) subgroups of essential hypertension (EHT), daily urinary excretions of renal K-K system components including kallikrein (KAL), total KAL, pre-KAL, kinin (KIN) and kininase (total, I and II), were measured in 21 normotensives (NT) and 45 patients with EHT (NRH: 29, LRH: 16). Urinary KAL and KIN quantities, KAL activity, total and pre-KAL, and kininase (total, I and II) were measured by direct RIA, kininogenase assay, direct RIA of KAL after trypsin treatment, and KIN destroying capacity, respectively. The daily excretions of KAL quantity and activity, total and pre-KAL, and KIN were significantly lower in EHT than in NT. That of total kininase and kininase I were significantly higher in EHT than in NT while no significant difference was found in kininase I between EHT and NT. In comparing NRH and LRH, the urinary KAL activity and KIN were lower in LRH than in NRH, and kininase I was higher in LRH than in NRH. No significant difference, however, was found in total and pre-KAL, KAL quantity and kininase II between NRH and LRH. The ratio of KAL quantity/total KAL which reflects the conversion rate from pre-KAL in the kidney, did not show any significant difference among NT, NRH and LRH.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D007705 Kinins A generic term used to describe a group of polypeptides with related chemical structures and pharmacological properties that are widely distributed in nature. These peptides are AUTACOIDS that act locally to produce pain, vasodilatation, increased vascular permeability, and the synthesis of prostaglandins. Thus, they comprise a subset of the large number of mediators that contribute to the inflammatory response. (From Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th ed, p588) Kinin
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001121 Lysine Carboxypeptidase A metallocarboxypeptidase that removes C-terminal basic amino acid from peptides and proteins, with preference shown for lysine over arginine. It is a plasma zinc enzyme that inactivates bradykinin and anaphylatoxins. Carboxypeptidase N,Kininase I,Anaphylatoxin Inactivator,Bradykininase,Carboxypeptidase, Lysine,Inactivator, Anaphylatoxin

Related Publications

Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
January 1980, Clinical and experimental hypertension,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
May 1978, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
August 1977, Japanese circulation journal,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
October 1979, Nihon rinsho. Japanese journal of clinical medicine,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
February 1984, Nihon rinsho. Japanese journal of clinical medicine,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
January 1989, Advances in experimental medicine and biology,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
December 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
January 1986, Kidney international,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
December 1992, Nihon rinsho. Japanese journal of clinical medicine,
Y Nakahashi, and K Shimamoto, and N Ura, and S Tanaka, and T Nishitani, and H Ishida, and T Yokoyama, and T Ando, and O Iimura
April 1992, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!